Skip to Content

Emmaus Life Sciences Inc EMMA

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, & commercialization of new treatments & therapies primarily for rare and orphan diseases. The company's commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its products in the pipeline include Diverticulosis and Cell Sheet Engineering.

Contact
21250 Hawthorne Boulevard, Suite 800
Torrance, CA, 90503
T +1 310 214-0065
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Dec 31, 2019
Fiscal Year End Dec 31, 2020
Stock Type Speculative Growth
Employees 55